All
Enterome announces presentation of data from ongoing Phase 1/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022
Enterome announces it will present updated efficacy, immunogenicity and safety data from its Phase 1/2 trial of EO2401 in combination with nivolumab +/- bevacizumab, in...
SITC oral presentation yesterday by Dr Reardon / update on EO2401 ROSALIE study in rGBM
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces...
MaaT Pharma Announces Participation in Scientific and Investor Conferences in November
MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients...
Clinical Microbiomics adds metabolomics to its portfolio with acquisition of MS-Omics to form the leading multi-omics provider for the microbiome field.
Clinical Microbiomics, a pioneering microbiome research
company, today announced its acquisition of MS-Omics, a leading metabolomics provider
based in Denmark.
Top VC Funds In France To Finance Your Startup
According to PitchBook data, France is Europe's second-largest VC hub by the amount of capital invested. The ecosystem is growing and expanding year by year, as it shows, in...
Launchmetrics launches visual content platform and invests in AI
Launchmetrics' expansion into the visual content sector began in 2019 with the acquisition of Italian company IMAXtree. The deal underscored the company's interest in...
Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study Evaluating a Potential First-In-Class Live Biotherapeutic Product for the Prevention of Atopic Diseases
Siolta Therapeutics, a clinical-stage biopharmaceutical company developing novel targeted live biotherapeutic products (LBPs) to prevent and treat diseases of high unmet...